A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India
Indian Journal of Hematology and Blood Transfusion · 2024-10 · 40 (4) · 710-714
DOI: 10.1007/s12288-024-01763-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Hematology and Blood Transfusion, online erschienen am 01.04.2024. Verfasst von Durba Biswas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine, Tata Medical Center, Newtown, Rajarhat, 700160 Kolkata, India. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The aim of this study is to analyze the profile of patients receiving daratumumab and their presentation to the transfusion laboratory by looking at the different pre-transfusion policies and the risk of erythrocyte alloimmunization. Patients receiving daratumumab from 2018 to 2023 were reviewed. They were divided into two groups: Group I, presented before administration of daratumumab, and Group II, presented after drug administration. Appropriate strategies were applied to mitigate the drug interference, and the transfusion outcome was analyzed by following up with the patients for six months. A total of 48 patients were studied. The antibody screen was negative in patients who presented before the administration of daratumumab (n = 35). Extended phenotyping was done for 31 patients. Blood group genotyping was done for 4 patients. The patients who presented after daratumumab administration (n = 13) had a positive antibody screen that became negative with dithiothreitol-treated cells. A total of 261 red cell units were transfused to these patients (mean 5.55 units per patient). None of the patients developed antibodies during the follow-up period. The transfusion services must frame policies and protocols to mitigate drug interference. Good communication between transfusion services and clinical hematologists is a must to ensure safe transfusions. Supplementary Information: The online version contains supplementary material available at 10.1007/s12288-024-01763-5.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Transfusion Medicine, Tata Medical Center, Newtown, Rajarhat, 700160 Kolkata, India.
- Department of Clinical Hematology and BMT, Tata Medical Center, Newtown, Rajarhat, 700160 Kolkata, India.
ORCID-Profile: Suvro Sankha Datta
Zitieren
APA
Biswas, D., Basu, D., Nag, A., Kumar, J., & Datta, S. S. (2024). A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India. Indian Journal of Hematology and Blood Transfusion, 40(4), 710-714. https://doi.org/10.1007/s12288-024-01763-5
Vancouver
Biswas D, Basu D, Nag A, Kumar J, Datta SS. A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India. Indian Journal of Hematology and Blood Transfusion. 2024;40(4):710-714. doi:10.1007/s12288-024-01763-5
BibTeX
@article{Biswas2024,
author = {Biswas, Durba and Basu, Debapriya and Nag, Arijit and Kumar, Jeevan and Datta, Suvro Sankha},
title = {A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India},
journal = {Indian Journal of Hematology and Blood Transfusion},
year = {2024},
volume = {40},
number = {4},
pages = {710--714},
doi = {10.1007/s12288-024-01763-5}
}
EUVIMED